POSIMIR市場：市場規模、予測、新たな洞察-2032年

浸潤に用いるPOSIMIR（SABER-ブピバカイン、旧名POSIDUR）は、660mgの強力なブピバカイン基剤と革新的なSABERプラットフォーム技術を組み合わせた新規の独自製品であり、成人において非オピオイド系局所鎮痛薬の3日間にわたる持続的な投与を可能にします。本剤は、局所アミド麻酔薬を含有し、関節鏡視下で肩峰下腔に投与することで、関節鏡視下肩峰下除圧術後72時間までの術後鎮痛に適応されます。

薬剤名の変更が定されたのは、FDAがPOSIDURに懸念を示したからです。2014年、米国の規制当局は同社に対し、研究者が安全に投与できることを証明する十分なデータを提供しておらず、追加の安全性試験が必要であると述べた。これは、後期臨床試験で有効性試験に不合格となった2年後のことでした。

作用機序

ブピバカインは神経の電気的興奮の閾値を上昇させ、神経インパルスの伝搬を遅らせ、活動電位の上昇速度を低下させることにより、神経インパルスの発生と伝導を遮断します。一般に、麻酔の進行は罹患した神経線維の直径、髄鞘、伝導速度に関係します。臨床的には、神経機能喪失の順序は（1）痛み、（2）温度、（3）触覚、（4）固有感覚、（5）骨格筋緊張です。

当レポートでは、主要7ヶ国におけるPOSIMIR市場について調査し、市場の概要とともに、競合情勢、2032年までの市場規模予測、および国別市場分析などを提供しています。

目次

第1章 レポートのイントロダクション

第2章 術後疼痛におけるPOSIMIRの概要

• 製品詳細
• 臨床開発
• 規制のマイルストーン
• その他の開発活動
• 製品プロファイル

第3章 競合情勢（上市済み治療法）

第4章 競合情勢（後期段階の新興治療法）

第5章 POSIMIR市場評価

• 術後疼痛におけるPOSIMIRの市場展望
• 主要7ヶ国分析
• 国別市場分析
  • 米国
  • ドイツ
  • 英国

第6章 SWOT分析

第7章 アナリストの見解

第8章 付録

第9章 DelveInsightのサービス内容

第10章 免責事項

第11章 DelveInsightについて

第12章 レポート購入オプション

List of Tables

• Table 1: POSIMIR, Clinical Trial Description, 2023
• Table 2: POSIMIR, General Description
• Table 3: Competitive Landscape (Marketed Therapies)
• Table 4: Competitive Landscape (Emerging Therapies)
• Table 5: POSIMIR Market Size in the 7MM, in USD million (2019-2032)
• Table 6: POSIMIR Market Size in the US, in USD million (2019-2032)
• Table 7: POSIMIR Market Size in Germany, in USD million (2019-2032)
• Table 8: POSIMIR Market Size in France, in USD million (2019-2032)
• Table 9: POSIMIR Market Size in Italy, in USD million (2019-2032)
• Table 10: POSIMIR Market Size in Spain, in USD million (2019-2032)
• Table 11: POSIMIR Market Size in the UK, in USD million (2019-2032)
• Table 12: POSIMIR Market Size in Japan, in USD million (2019-2032)

List of Figures

• Figure 1: POSIMIR Market Size in the 7MM, USD million (2019-2032)
• Figure 2: POSIMIR Market Size in the United States, USD million (2019-2032)
• Figure 3: POSIMIR Market Size in Germany, USD million (2019-2032)
• Figure 4: POSIMIR Market Size in France, USD million (2019-2032)
• Figure 5: POSIMIR Market Size in Italy, USD million (2019-2032)
• Figure 6: POSIMIR Market Size in Spain, USD million (2019-2032)
• Figure 7: POSIMIR Market Size in the United Kingdom, USD million (2019-2032)
• Figure 8: POSIMIR Market Size in Japan, USD million (2019-2032)

"POSIMIR Market Size, Forecast, and Market Insight - 2032" report provides comprehensive insights about POSIMIR for Postoperative pain in the seven major markets. A detailed picture of the POSIMIR for Postoperative pain in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the POSIMIR for Postoperative pain. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the POSIMIR market forecast analysis for Postoperative pain in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in Postoperative pain.

Drug Summary:

POSIMIR (SABER-bupivacaine, also previously known as POSIDUR) for infiltration use is a novel and proprietary product that combines the strength of 660 mg of bupivacaine base with the innovative SABER platform technology, enabling continuous sustained delivery of a non-opioid local analgesic over 3 days in adults. It contains a local amide anesthetic and is indicated in adults for administration into the subacromial space under direct arthroscopic visualization to produce postsurgical analgesia for up to 72 h following arthroscopic subacromial decompression.

The company decided to change the drug's name because the FDA was concerned with POSIDUR. In 2014, the US regulator told the company that investigators did not provide sufficient data to prove that it could be safely administered and would need additional safety studies. This came 2 years after the program failed an efficacy test in a late-stage study.

Mechanism of action

Bupivacaine blocks the generation and the conduction of nerve impulses by increasing the threshold for electrical excitation in the nerve, slowing the nerve impulses propagation, and reducing the rate of rise of the action potential. In general, the progression of anesthesia is related to the diameter, myelination, and conduction velocity of affected nerve fibers. Clinically, the order of a loss of nerve function is as follows: (1) pain, (2) temperature, (3) touch, (4) proprioception, and (5) skeletal muscle tone.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the POSIMIR description, mechanism of action, dosage and administration, research and development activities in Postoperative pain.
• Elaborated details on POSIMIR regulatory milestones and other development activities have been provided in this report.
• The report also highlights the POSIMIR research and development activities in Postoperative pain across the United States, Europe, and Japan.
• The report also covers the patents information with expiry timeline around POSIMIR.
• The report contains forecasted sales of POSIMIR for Postoperative pain till 2032.
• Comprehensive coverage of the late-stage emerging therapies for Postoperative pain.
• The report also features the SWOT analysis with analyst views for POSIMIR in Postoperative pain.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

POSIMIR Analytical Perspective by DelveInsight

• In-depth POSIMIR Market Assessment

This report provides a detailed market assessment of POSIMIR for Postoperative pain in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2024 to 2032.

• POSIMIR Clinical Assessment

The report provides the clinical trials information of POSIMIR for Postoperative pain covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for Postoperative pain is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence POSIMIR dominance.
• Other emerging products for Postoperative pain are expected to give tough market competition to POSIMIR and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of POSIMIR in Postoperative pain.
• Our in-depth analysis of the forecasted sales data of POSIMIR from 2024 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the POSIMIR in Postoperative pain.

Key Questions:

• What is the product type, route of administration and mechanism of action of POSIMIR?
• What is the clinical trial status of the study related to POSIMIR in Postoperative pain and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the POSIMIR development?
• What are the key designations that have been granted to POSIMIR for Postoperative pain?
• What is the forecasted market scenario of POSIMIR for Postoperative pain?
• What are the forecasted sales of POSIMIR in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to POSIMIR for Postoperative pain?
• Which are the late-stage emerging therapies under development for the treatment of Postoperative pain?

Table of Contents

1. Report Introduction

2. POSIMIR Overview in Postoperative pain

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Regulatory Milestones
• 2.4. Other Developmental Activities
• 2.5. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. POSIMIR Market Assessment

• 5.1. Market Outlook of POSIMIR in Postoperative pain
• 5.2. 7MM Analysis
  • 5.2.1. Market Size of POSIMIR in the 7MM for Postoperative pain
• 5.3. Country-wise Market Analysis
  • 5.3.1. Market Size of POSIMIR in the United States for Postoperative pain
  • 5.3.2. Market Size of POSIMIR in Germany for Postoperative pain
  • 5.3.3. Market Size of POSIMIR in France for Postoperative pain
  • 5.3.4. Market Size of POSIMIR in Italy for Postoperative pain
  • 5.3.5. Market Size of POSIMIR in Spain for Postoperative pain
  • 5.3.6. Market Size of POSIMIR in the United Kingdom for Postoperative pain
  • 5.3.7. Market Size of POSIMIR in Japan for Postoperative pain

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options